YLT-11
YLT-11 is a potent, selective and orally active PLK4 inhibitor with Kd values of >10000, 653, >10000, 5.2 nM for PLK1, PLK2, PLK3, PLK4, respectively. YLT-11 shows antiproliferative activity. YLT-11 induces Apoptosis and cell cycle arrest at G2/M phase. YLT-11 show anticancer activity[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; Polo-like Kinase (PLK)
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ylt-11.html
Solubility
10 mM in DMSO
Smiles
CC(NC1=NC=CC(C2=CC3=C(C=C2)C(/C=C/C4=CC=C(CN(C)C)C=C4)=NN3)=N1)=O
Molecular Formula
C24H24N6O
Molecular Weight
412.49
References & Citations
[1]Lei Q, et al. YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect. Cell Death Dis. 2018 Oct 18;9 (11) :1066.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PLK1; PLK2; PLK3; PLK4
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
D8970 96 Tests
Guanine nucleotide-binding protein G (GNAI1) Human ELISA Kit
Sign In for Pricing
View Details 